These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 28507219)

  • 1. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
    Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Pacheco-Tena C; Louw I; Vega-Cornejo G; Spindler AJ; Kingsbury DJ; Schmeling H; Borzutzky A; Cuttica R; Inman CJ; Malievskiy V; Scott C; Keltsev V; Terreri MT; Viola DO; Xavier RM; Fernandes TAP; Velázquez MDRM; Henrickson M; Clark MB; Bensley KA; Li X; Lo KH; Leu JH; Hsu CH; Hsia EC; Xu Z; Martini A; Lovell DJ;
    Rheumatology (Oxford); 2021 Oct; 60(10):4495-4507. PubMed ID: 33493312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
    Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
    Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z
    Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.